Comparative Effectiveness of Once-Weekly Insulin Efsitora Alfa in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Аннотация
BACKGROUND
Achieving and maintaining a glycated hemoglobin (HbA1c) level <7% in patients with type 2 diabetes (T2D) remains challenging, partly because of the daily insulin injection burden. Insulin efsitora alfa is a long-acting insulin Fc-fusion protein designed for once-weekly administration, which may reduce injection burden.
PURPOSE: The purpose of this analysis is to evaluate the efficacy and safety of once-weekly insulin efsitora alfa compared with once-daily basal insulin in adults with T2D, stratified by baseline insulin use.
DATA SOURCES: PubMed, Web of Science, Scopus, and Cochrane CENTRAL were searched from inception through July 2025, along with ClinicalTrials.gov.
STUDY SELECTION: Randomized controlled trials (RCTs) enrolling adults with T2D that compared once-weekly insulin efsitora alfa with once-daily basal insulin for ≥12 weeks were included. Six trials met eligibility criteria.
DATA EXTRACTION: Two authors independently extracted data using a standardized form. The primary outcome was the mean change in HbA1c (%). Secondary outcomes included fasting plasma glucose, body weight, time in range, hypoglycemia, and adverse events. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool.
DATA SYNTHESIS: Six RCTs, including 4,116 participants, were analyzed. Efsitora demonstrated HbA1c reduction comparable to daily basal insulin in insulin-treated patients (mean difference [MD] -0.06% [95% CI -0.24, 0.11]; P = 0.48) and insulin-naive patients (MD -0.03% [95% CI -0.12, 0.06]; P = 0.51). Nocturnal hypoglycemia episodes were fewer with efsitora in both insulin-treated patients (risk ratio [RR] 0.82 [95% CI 0.68, 0.98]; P = 0.03) and insulin-naive patients (RR 0.71 [95% CI 0.52, 0.95]; P = 0.02).
LIMITATIONS: All included trials were open-label, and follow-up duration was limited. Long-term outcomes, real-world adherence, and cost-effectiveness could not be fully assessed.
CONCLUSIONS
Once-weekly insulin efsitora alfa demonstrates glycemic control and overall safety comparable to once-daily basal insulin in adults with T2D, with fewer nocturnal hypoglycemia episodes. Longer-term RCTs and real-world studies are needed to define its long-term clinical and economic impact.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.